Interferon-β-1b: A review of its use in multiple sclerosis

CNS Drugs

Volumn 25, Issue 1, 2011, Pages 67-88

  Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Evaluations; Interferon beta 1b, general; Multiple sclerosis

Indexed keywords

ANALGESIC AGENT; BETA1A INTERFERON; CLADRIBINE; FINGOLIMOD; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; NATALIZUMAB; NEUTRALIZING ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CHILL; CLINICAL ASSESSMENT; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DEPRESSION; DISEASE COURSE; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; ECONOMIC ASPECT; EXPANDED DISABILITY STATUS SCALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HUMAN; INJECTION SITE DISCOLORATION; INJECTION SITE HYPERSENSITIVITY; INJECTION SITE INFLAMMATION; INJECTION SITE NECROSIS; INJECTION SITE REACTION; INJECTION SITE REDNESS; INJECTION SITE SWELLING; LEUKOCYTE COUNT; LONG TERM CARE; LYMPHADENOPATHY; LYMPHOCYTOPENIA; MALAISE; MULTIPLE SCLEROSIS; MYALGIA; NEUTROPHIL COUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RASH; RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; SUICIDAL IDEATION; SWEATING; SYSTOLIC DYSFUNCTION; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 78649921481     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11206430-000000000-00000     Document Type: Review

References (77)

1. World Health Organization, Multiple Sclerosis Inter- national Federation. Atlas: multiple sclerosis resources in the world, 2008 [online]. Available from URL: http://www. msif.org/en/about-msif/what-we-do/atlas-of-ms/ [Accessed 2010 Jul 30].
2. National Multiple Sclerosis Society. Who gets MS? [online]. Available from URL: http://www.nationalmssociety.org/ about-multiple-slcerosis/what-we- know-about-ms/who-gets-ms/index.aspx [Accessed 2010 Jul 30].
3. Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 2009; 65: 239-48.
4. Pugliatti M, Rosati G, Carton H, et al. The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006; 13: 700-22.
5. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996 Apr; 46 (4): 907-11.
6. Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000 Nov 16; 343 (20): 1430-8.
7. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989 Feb; 112 Pt 1: 133-46.
8. Leary SM, Thompson AJ. Primary progressive multiple sclerosis: current and future treatment options. CNS Drugs 2005; 19 (5): 369-76.
9. Thompson AJ, Montalban X, Barkhof F, et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 2000 Jun; 47 (6): 831-5.
10. Comi G. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta. Clin Ther 2009 Jun; 31 (6): 1142-57.
11. Stuve O, Bennett JL, Hemmer B, et al. Pharmacological treatment of early multiple sclerosis. Drugs 2008; 68 (1): 73-83.
12. Freedman MS, Hughes B, Mikol DD, et al. Efficacy of dis- ease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison. Eur Neurol 2008; 60 (1): 1-11.
13. Goodin DS. Disease-modifying therapy in multiple sclero- sis: update and clinical implications. Neurology 2008 Dec 9; 71 (24 Suppl. 3): S8-13.
14. Goodin DS, Frohman EM, Garmany Jr GP, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002 Jan 22; 58 (2): 169-78.
15. Giovannoni G. Management of secondary-progressive multiple sclerosis. CNS Drugs 2004; 18 (10): 653-69.
16. McKeage K. Interferon-beta-1b: in newly emerging multiple sclerosis. CNS Drugs 2008; 22 (9): 787-92.
17. McCormackPL, Scott LJ. Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis. CNS Drugs 2004; 18 (8): 521-46.
18. Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 2002 Apr 23; 58 (8 Suppl. 4): S3-9.
19. Bayer HealthCare - Bayer Schering Pharma. Betaferon® (recombinant interferon beta-1b powder and solvent for solution for injection): summary of product characteristics [online]. Available from URL: http://www.medicines.org. uk/EMC/medicine/1809/SPC/Betaferon [Accessed 2010 Jul 20].
20. Bayer HealthCare Pharmaceuticals. Betaseron® (interferon beta-1b for subcutaneous injection): US prescribing information [online]. Available from URL: http://berlex. bayerhealthcare.com/html/products/pi/Betaseron-PI.pdf [Accessed 2010 Jul 29].
21. Williams GJ, Witt PL. Comparative study of the pharma- codynamic and pharmacologic effects of Betaseron and Avonex. J Interferon Cytokine Res 1998 Nov; 18 (11): 967-75.
22. Bertolotto A, Gilli F, Sala A, et al. Evaluation of bio- availability of three types of IFN-beta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Methods 2001; 256 (1-2): 141-52.
23. Sturzebecher S, Maibauer R, Heuner A, et al. Pharmaco- dynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers. J Interferon Cytokine Res 1999; 19 (11): 1257-2126.
24. Malucchi S, Gilli F, Caldano M, et al. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 2008 Mar 2; 70 (13): 1119-27.
25. Deisenhammer F. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes. CNS Drugs 2009; 23 (5): 379-96.
26. Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007 Mar 27; 68 (13): 977-84.
27. European Study Group on Interferon beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998 Nov 7; 352: 1491-7.
28. Durelli L, Verdun E, Barbero P, et al. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002 Apr 27; 359 (9316): 1453-60.
29. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006 Oct 10; 67 (7): 1242-9.
30. North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004 Nov 23; 63 (10): 1788-95.
31. The IFNB Multiple Sclerosis Study Group. Interferon beta- 1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993 Apr; 43 (4): 655-61.
32. Sorensen PS, Ross C, Clemmesen KM, et al. Clinical im- portance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003 Oct 11; 362 (9391): 1184-91.
33. Chiang J, Gloff CA, Yoshizawa CN, et al. Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin. Pharm Res 1993 Apr; 10 (4): 567-72.
34. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983 Nov; 33 (11): 1444-52.
35. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007 Aug 4; 370 (9585): 389-97.
36. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009 Nov; 8 (11): 987-97.
37. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
38. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-7.
39. Barkhof F, Polman CH, Radue EW, et al. Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. Arch Neurol 2007 Sep; 64 (9): 1292-8.
40. Sahraian MA, Radue EW, Haller S, et al. Black holes in multiple sclerosis: definition, evolution, and clinical correlations. Acta Neurol Scand 2010 Jul; 122 (1): 1-8.
41. Foley F, Benedict R, Penner I-K, et al. Treatment effects of IFNB-1b on paced auditory serial addition test performance in patients with a first event suggestive of MS [abstract no. P-807 plus poster]. 26th Congressofthe European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2010 Oct 13-16; Gothenburg.
42. Koch-Henriksen N, Sorensen PS, Christensen T, et al. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology 2006 Apr 11; 66 (7): 1056-60.
43. O'Connor P, Filippi M, Arnason B, et al. 250ug or 500 ug interferon beta-1b versus 20mg glatiramer acetate in re-lapsing-remitting multiple sclerosis: a prospective, ran- domised, multicentre study. Lancet Neurol 2009 Oct; 8 (10): 889-97.
44. Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009 Jun 9; 72 (23): 1976-83.
45. Paty DW, Li DK. Interferon beta-1b is effective in relapsing- remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993 Apr; 43 (4): 662-7.
46. The IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995 Jul; 45: 1277-85.
47. Ross C, Clemmesen KM, Svenson M, et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Ann Neurol 2000; 48 (5): 706-12.
48. Fillipi M, Rocca MA, Camesasca F, et al. IFNB-1b com- pared with GA therapy for reducing evolution of permanent T1 hypointensities ("black holes") on brain MRI in treatment-naive RRMS patients [abstract no. PO5.054 plus poster]. 62nd Annual Meeting of the American Academy of Neurology; 2010 Apr 10-17; Toronto.
49. Fillipi M, Rocca MA, Camesasca F, et al. T1-hypointense permanent black holes in RRMS patients treated with interferon beta-1b and glatiramer acetate [abstract no. P-476 plus poster]. 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2010 Oct 13-16; Gothenburg.
50. Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta- 1b in secondary progressive MS: a combined analysis of the two trials. Neurology 2004 Nov 23; 63 (10): 1779-87.
51. Barkhof F, van Waesberghe JH, Filippi M, et al. T(1) hy- pointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. Brain 2001 Jul; 124 (Pt 7): 1396-402.
52. Brex PA, Molyneux PD, Smiddy P, et al. The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS. Neurology 2001 Dec 26; 57 (12): 2185-90.
53. Freeman JA, Thompson AJ, Fitzpatrick R, et al. Interferon- beta1b in the treatment of secondary progressive MS: impact on quality of life. Neurology 2001 Nov 27; 57 (10): 1870-5.
54. Reder AT, O'Connor P, Kappos L, et al. Short- and long- term safety and tolerability of interferon-beta-1b in multiple sclerosis [abstract no. S105 plus poster]. 24th Annual Meeting of the Consortium of Multiple Sclerosis Centers; 2010 Jun 2-5; San Antonio (TX).
55. Reder AT, Ebers GC, Traboulsee A, et al. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. Neurology 2010 Jun 8; 74 (23): 1877-85.
56. Ebers GC, Reder AT, Traboulsee A, et al. Long-term fol- low-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study. Clin Ther 2009 Aug; 31 (8): 1724-36.
57. Reder AT, Ebers G, Cutter G, et al. Survival analysis 21 years after the initiation of the pivotal interferon beta-1b trial in patients with RRMS [abstract no. P-903 plus poster]. 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); 2010 Oct 13-16; Gothenburg.
58. Bell C, Graham J, Earnshaw S, et al. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm 2007 Apr; 13 (3): 245-61.
59. Chilcott J, McCabe C, Tappenden P, et al. Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Br Med J 2003; 326 (7388): 522-5.
60. Goldberg LD, Edwards NC, Fincher C, et al. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. J Manag Care Pharm 2009 Sep; 15 (7): 543-55.
61. Nuijten M, Mittendorf T. A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective. Clin Ther 2010 Apr; 32 (4): 717-28.
62. Tappenden P, McCabe C, Chilcott J, et al. Cost-effective- ness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population. Value Health 2009; 12 (5): 657-65.
63. Touchette DR, Durgin TL, Wanke LA, et al. A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis. Clin Ther 2003 Feb; 25 (2): 611-34.
64. National Institute for Clinical Excellence. Beta interferon and glatiramer acetate for the treatment of multiple sclerosis: technology appraisal guidance -no. 32. London: National Institute for Clinical Excellence, 2002.
65. Gani R, Giovannoni G, Bates D, et al. Cost-effectiveness analyses of natalizumab (Tysabri®) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharma-coeconomics 2008; 26 (7): 617-27.
66. Association of British Neurologists. Revised (2009) guide- lines for prescribing in multiple sclerosis [online]. Available from URL: http://www.theabn.org/abn/userfiles/file/ABN- MS-Guidelines-2009-Final.pdf [Accessed 2010 Aug 13].
67. Compston A, Coles A. Multiple sclerosis. Lancet 2008 Oct 25; 372(9648): 1502-17.
68. Menge T, Weber MS, Hemmer B, et al. Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs 2008; 68 (17): 2445-68.
69. Multiple Sclerosis Therapy Consensus Group. Escalating immunotherapy of multiple sclerosis: new aspects and practical application. J Neurol 2004 Nov; 251 (11): 1329-39.
70. National Institute for Clinical Excellence. Multiple sclerosis: management of multiple sclerosis in primary and secondary care [online]. Available from URL: http://www.nice. org.uk/nicemedia/pdf/cg008guidance.pdf [Accessed 2010 Aug 13].
71. Carter NJ, Keating GM. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. Drugs 2010; 70 (12): 1545-77.
72. Marriott JJ, Miyasaki JN, Gronseth G, et al. Evidence re- port: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcomittee of the American Academy of Neurology. Neurology 2010 May 4; 74 (18): 1463-70.
73. Multiple sclerosis drug Gilenya (fingolimod) approved by FDA [online]. Available from URL http://www.medical newstoday.com/printerfriendlynews.php? newsid=20219 [Accessed 2010 Sep 29].
74. Jeffrey S. European regulators issue negative opinion on cladribine for multiple sclerosis [online]. Available from URL: http://www.medscape.com/ viewarticle/729387 [Accessed 2010 Sep 27].
75. Oral laquinimod for multiple sclerosis granted fast track status by FDA [online]. Available from URL http:// www.medicalnewstoday.com/ pritnerfriendlynews.php? newsid=139148 [Accessed 2010 Sep 29].
76. Carroll WM. Oral therapy for multiple sclerosis: sea change or incremental step? N Engl J Med 2010 Feb 4;362 (5): 456-8.
77. Conway D, Cohen JA. Combination therapy in multiple sclerosis. Lancet Neurol 2010 Mar; 9 (3): 299-308